Joseph J. Ferra Jr. - 16 Jun 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
16 Jun 2025
Net transactions value
-$1,783
Form type
4
Filing time
18 Jun 2025, 16:15:13 UTC
Previous filing
19 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ferra Joseph J Jr CHIEF EXECUTIVE OFFICER, Director C/O ELEVATION ONCOLOGY, INC., 101 FEDERAL STREET, SUITE 1900, BOSTON /s/ Robert Yang, Attorney-in-Fact 18 Jun 2025 0001733790

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +12,560 +9.2% 149,712 16 Jun 2025 Direct F1
transaction ELEV Common Stock Tax liability $1,783 -4,627 -3.1% $0.3854 145,085 16 Jun 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -12,560 -100% $0.000000 0 16 Jun 2025 Common Stock 12,560 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on June 16, 2022, and the remainder vested as to 1/16 of the total RSUs quarterly.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.